CPHI 2025: time for European biopharma to double down on innovation
European biotechs should leverage its innovation and collaborate with Asian manufacturing hubs to secure greater investment, say experts.
Drug Manufacturers
Lifecore and PolyPeptide link for US peptide manufacturing
AstraZeneca doubles Lokelma output with $445m Texas plant expansion
BIOSECURE returns to US pharma agenda with 2.0 update
FDA ‘green list’ flagging illegal GLP-1RA compounders is long overdue
AstraZeneca sets $4.5bn Virginia API plant construction in motion
Halozyme eyes microparticles in $900m Elektrofi acquisition
Eli Lilly to build $6.5bn orforglipron production site in Texas
